Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
08:02pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
Underwriters’ full exercise of option brings gross proceeds to $264.5 million Underwriters’ full exercise of option brings gross proceeds to $264.5 million
Revolution Medicines Stock Is Getting Hammered: Here's Why
10:32am, Wednesday, 20'th Jul 2022
Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
02:41am, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ann
Revolution Medicines Announces Commencement of Public Offering of Common Stock
08:01pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ann
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?
01:42pm, Friday, 24'th Jun 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
08:02pm, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ann
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
04:02pm, Thursday, 09'th Jun 2022
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
02:02pm, Friday, 20'th May 2022 Benzinga
Upgrades
For Telia Company AB (OTC:TLSNY), UBS upgraded the previous rating of Neutral to Buy. For the first quarter, Telia Company had an EPS of $0.05, compared to year-ago quarter EPS of $0.03. The
Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q1 2022 Results - Earnings Call Transcript
04:00am, Tuesday, 10'th May 2022
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants David Errington - Senior Vice President of Investor Relations & Corporate Affairs
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates
09:35pm, Monday, 09'th May 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates
06:48pm, Monday, 09'th May 2022
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Select Medical (SEM) Beats Q1 Earnings and Revenue Estimates
12:05am, Friday, 06'th May 2022 Zacks Investment Research
Select Medical (SEM) delivered earnings and revenue surprises of 27.59% and 2.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?
11:45am, Monday, 04'th Apr 2022 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in th
7 Stocks That Insiders Are Buying Now. Should You?
08:33am, Thursday, 31'st Mar 2022
Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revol
Children's Place And 2 Other Stocks Bought By Insiders
12:21pm, Friday, 25'th Mar 2022 Benzinga
Although US stock futures traded higher this morning on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that
